BPMUF Stock - Basilea Pharmaceutica AG
Unlock GoAI Insights for BPMUF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $208.54M | $157.63M | $147.76M | $148.12M | $127.63M |
| Gross Profit | $169.86M | $130.84M | $123.16M | $124.05M | $103.58M |
| Gross Margin | 81.5% | 83.0% | 83.3% | 83.7% | 81.2% |
| Operating Income | $61.18M | $19.20M | $18.54M | $1.19M | $-8,222,000 |
| Net Income | $77.59M | $10.45M | $12.15M | $-6,831,000 | $-14,722,000 |
| Net Margin | 37.2% | 6.6% | 8.2% | -4.6% | -11.5% |
| EPS | $6.42 | $0.86 | $1.02 | $-0.58 | $-1.43 |
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.
Visit WebsiteEarnings History & Surprises
BPMUFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 16, 2026 | — | — | — | — |
Q3 2025 | Aug 19, 2025 | $2.56 | $1.44 | -43.8% | ✗ MISS |
Q1 2025 | Feb 18, 2025 | $3.57 | $4.52 | +26.6% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $1.30 | $1.67 | +28.5% | ✓ BEAT |
Q2 2024 | Apr 24, 2024 | $-2.38 | $-2.08 | +12.5% | ✓ BEAT |
Q2 2023 | Jun 30, 2023 | $0.90 | $2.58 | +187.0% | ✓ BEAT |
Q4 2022 | Dec 31, 2022 | $-1.41 | $2.20 | +256.5% | ✓ BEAT |
Q2 2022 | Jun 30, 2022 | $-1.62 | $-1.08 | +33.6% | ✓ BEAT |
Q4 2021 | Dec 31, 2021 | $0.08 | $1.21 | +1477.0% | ✓ BEAT |
Q2 2021 | Jun 30, 2021 | $-1.66 | $-1.86 | -12.5% | ✗ MISS |
Q4 2020 | Dec 31, 2020 | $-2.96 | $-2.57 | +13.4% | ✓ BEAT |
Q2 2020 | Jun 30, 2020 | $-1.49 | $0.97 | +165.1% | ✓ BEAT |
Q4 2019 | Dec 31, 2019 | $-1.10 | $-0.66 | +40.0% | ✓ BEAT |
Q2 2019 | Jun 30, 2019 | — | $-1.47 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-0.83 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-2.08 | — | — |
Q4 2017 | Dec 31, 2017 | — | $0.11 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-1.98 | — | — |
Q4 2016 | Dec 31, 2016 | — | $-2.26 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-2.83 | — | — |
Latest News
Frequently Asked Questions about BPMUF
What is BPMUF's current stock price?
What is the analyst price target for BPMUF?
What sector is Basilea Pharmaceutica AG in?
What is BPMUF's market cap?
Does BPMUF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BPMUF for comparison